

ATRIX LABORATORIES INC

Form 8-K

September 23, 2003

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported)

September 22, 2003

**ATRIX LABORATORIES, INC.**

(Exact Name of Registrant as Specified in Charter)

Delaware

0-18231

84-1043826

(State or Other  
Jurisdiction of  
Incorporation)

(Commission File No.)

(IRS Employer  
Identification No.)

2579 Midpoint Drive, Fort Collins, Colorado

80525

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code

(970) 482-5868

**TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EX-99.1 Press Release

---

**Table of Contents**

Item 5. Other Events.

On September 22, 2003, Atrix Laboratories, Inc. (the Company ) issued a press release announcing that it will be presenting at the UBS Warburg Global Life Sciences Conference in New York where it will be discussing the Company s prospects, opportunities, and challenges, including the financial challenges related to the goal of breaking even for 2003 and providing an update on Eligard® (leuprolide acetate for injectable suspension) prostate cancer products. A copy of the press release is attached as Exhibit 99.1 to this report.

Item 7. Exhibits.

99.1 Press Release dated September 22, 2003.

---

**Table of Contents**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRIX LABORATORIES, INC

By: /s/ Mark A. Wallace

\_\_\_\_\_  
Mark A. Wallace  
Chief Financial Officer

Date: September 23, 2003

---

**Table of Contents**

EXHIBIT INDEX

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release dated September 22, 2003.